Logo image of PRLD

PRELUDE THERAPEUTICS INC (PRLD) Stock Fundamental Analysis

NASDAQ:PRLD - Nasdaq - US74065P1012 - Common Stock - Currency: USD

0.9387  +0.14 (+17.53%)

After market: 0.9599 +0.02 (+2.26%)

Fundamental Rating

2

Overall PRLD gets a fundamental rating of 2 out of 10. We evaluated PRLD against 568 industry peers in the Biotechnology industry. PRLD scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. PRLD does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

PRLD had negative earnings in the past year.
In the past year PRLD has reported a negative cash flow from operations.
PRLD had negative earnings in each of the past 5 years.
In the past 5 years PRLD always reported negative operating cash flow.
PRLD Yearly Net Income VS EBIT VS OCF VS FCFPRLD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

The Return On Assets of PRLD (-72.46%) is worse than 65.85% of its industry peers.
PRLD has a Return On Equity (-96.74%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -72.46%
ROE -96.74%
ROIC N/A
ROA(3y)-56.23%
ROA(5y)-46.15%
ROE(3y)-69.07%
ROE(5y)-54.62%
ROIC(3y)N/A
ROIC(5y)N/A
PRLD Yearly ROA, ROE, ROICPRLD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for PRLD so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PRLD Yearly Profit, Operating, Gross MarginsPRLD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -500 -1K -1.5K

More info and screens

5

2. Health

2.1 Basic Checks

PRLD does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, PRLD has more shares outstanding
The number of shares outstanding for PRLD has been increased compared to 5 years ago.
PRLD has a worse debt/assets ratio than last year.
PRLD Yearly Shares OutstandingPRLD Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
PRLD Yearly Total Debt VS Total AssetsPRLD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

PRLD has an Altman-Z score of -5.89. This is a bad value and indicates that PRLD is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of PRLD (-5.89) is worse than 63.20% of its industry peers.
PRLD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -5.89
ROIC/WACCN/A
WACC10.28%
PRLD Yearly LT Debt VS Equity VS FCFPRLD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

PRLD has a Current Ratio of 5.30. This indicates that PRLD is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 5.30, PRLD is in line with its industry, outperforming 57.04% of the companies in the same industry.
A Quick Ratio of 5.30 indicates that PRLD has no problem at all paying its short term obligations.
PRLD has a Quick ratio (5.30) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 5.3
Quick Ratio 5.3
PRLD Yearly Current Assets VS Current LiabilitesPRLD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

3

3. Growth

3.1 Past

PRLD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 16.75%, which is quite good.
EPS 1Y (TTM)16.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%17.39%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

PRLD is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 8.08% yearly.
The Revenue is expected to grow by 120.17% on average over the next years. This is a very strong growth
EPS Next Y2.14%
EPS Next 2Y16.76%
EPS Next 3Y13.05%
EPS Next 5Y8.08%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y120.17%

3.3 Evolution

PRLD Yearly Revenue VS EstimatesPRLD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2024 2028 2029 2030 2031 2032 100M 200M 300M
PRLD Yearly EPS VS EstimatesPRLD Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -1 -2 -3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

PRLD reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year PRLD is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PRLD Price Earnings VS Forward Price EarningsPRLD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PRLD Per share dataPRLD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

PRLD's earnings are expected to grow with 13.05% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.76%
EPS Next 3Y13.05%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for PRLD!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PRELUDE THERAPEUTICS INC

NASDAQ:PRLD (4/22/2025, 7:04:55 PM)

After market: 0.9599 +0.02 (+2.26%)

0.9387

+0.14 (+17.53%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-10 2025-03-10/bmo
Earnings (Next)05-13 2025-05-13/bmo
Inst Owners50.59%
Inst Owner Change-0.57%
Ins Owners9.43%
Ins Owner Change31.23%
Market Cap51.77M
Analysts77.78
Price Target5.1 (443.3%)
Short Float %10.03%
Short Ratio9.4
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)15.12%
Min EPS beat(2)10.65%
Max EPS beat(2)19.59%
EPS beat(4)3
Avg EPS beat(4)10.12%
Min EPS beat(4)-4.88%
Max EPS beat(4)19.59%
EPS beat(8)7
Avg EPS beat(8)13.26%
EPS beat(12)11
Avg EPS beat(12)10.59%
EPS beat(16)11
Avg EPS beat(16)6.11%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0.71%
EPS NQ rev (3m)-8.53%
EPS NY rev (1m)-8.27%
EPS NY rev (3m)-8.27%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 7.4
P/FCF N/A
P/OCF N/A
P/B 0.39
P/tB 0.39
EV/EBITDA N/A
EPS(TTM)-1.69
EYN/A
EPS(NY)-1.65
Fwd EYN/A
FCF(TTM)-1.88
FCFYN/A
OCF(TTM)-1.87
OCFYN/A
SpS0.13
BVpS2.38
TBVpS2.38
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -72.46%
ROE -96.74%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-56.23%
ROA(5y)-46.15%
ROE(3y)-69.07%
ROE(5y)-54.62%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.04
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 43.12%
Cap/Sales 10.91%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.3
Quick Ratio 5.3
Altman-Z -5.89
F-Score4
WACC10.28%
ROIC/WACCN/A
Cap/Depr(3y)190.81%
Cap/Depr(5y)187.88%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)16.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%17.39%
EPS Next Y2.14%
EPS Next 2Y16.76%
EPS Next 3Y13.05%
EPS Next 5Y8.08%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y120.17%
EBIT growth 1Y-5.61%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-15.26%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y6.26%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y3.9%
OCF growth 3YN/A
OCF growth 5YN/A